{
  "ticker": "NOX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973209",
  "id": "02973209",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0939",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6dws8rvfdfz.pdf",
  "summary": "- **HERACLES Clinical Trial Update**:  \n  - First dose cohort of SOF-SKN\u2122 completed with no safety issues; trial progresses to higher-dose cohort.  \n  - Trial focuses on safety, tolerability, and dose escalation for autoimmune diseases (e.g., cutaneous lupus erythematosus).  \n  - Potential market opportunity: Global CLE market valued at >US$3.3 billion.  \n\n*No material capital markets or trading-specific information (e.g., funding, timelines, or liquidity impacts) identified.*",
  "usage": {
    "prompt_tokens": 1705,
    "completion_tokens": 106,
    "total_tokens": 1811,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:49:16.243226"
}